Erratum: Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

被引：0
|
作者：
D S Siegel
P Richardson
M Dimopoulos
P Moreau
C Mitsiades
D Weber
J Houp
C Gause
S Vuocolo
J Eid
T Graef
K C Anderson
机构：
[1] John Theurer Cancer Center,Myeloma Division
[2] Hackensack University Medical Center,Department of Clinical Therapeutics
[3] Dana-Farber Cancer Institute,Department of Medicine
[4] University of Athens,undefined
[5] University Hospital,undefined
[6] MD Anderson Cancer Center,undefined
[7] Merck & Co. Inc.,undefined
[8] Pharmacyclics Inc.,undefined
[9] Harvard Medical School and Kraft Family Blood Center,undefined
[10] Dana-Farber Cancer Institute,undefined
来源：
Blood Cancer Journal | 2014年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Correction to: Blood Cancer Journal (2014) 4, e182; doi:10.1038/bcj.2014.1; published online 21 February 2014 Since the publication of this article, the authors have identified an error concerning one of the author affiliation addresses. KC Anderson was incorrectly affiliated to the following address: ‘Merck & Co.
引用
收藏
页码：e202 / e202
相关论文
共 50 条
  • [1] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
    Siegel, D. S.
    Richardson, P.
    Dimopoulos, M.
    Moreau, P.
    Mitsiades, C.
    Weber, D.
    Houp, J.
    Gause, C.
    Vuocolo, S.
    Eid, J.
    Graef, T.
    Anderson, K. C.
    [J]. BLOOD CANCER JOURNAL, 2014, 4 : e182 - e182
  • [2] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
    D S Siegel
    P Richardson
    M Dimopoulos
    P Moreau
    C Mitsiades
    D Weber
    J Houp
    C Gause
    S Vuocolo
    J Eid
    T Graef
    K C Anderson
    [J]. Blood Cancer Journal, 2014, 4 : e182 - e182
  • [3] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study
    Siegel, D. S.
    Weber, D. M.
    Mitsiades, C. S.
    Dimopoulos, M. A.
    Harousseau, J. L.
    Rizvi, S.
    Howe, J.
    Reiser, D.
    Anderson, K. C.
    Richardson, P. G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Siegel, David
    Weber, Donna
    Mitsiades, Constantine S.
    Rizvi, Syed
    Garcia-Vargas, Jose
    Howe, Jason
    Reiser, David
    Anderson, Kenneth C.
    Richardson, Paul
    [J]. BLOOD, 2008, 112 (11) : 1270 - 1270
  • [5] Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma
    Bilotti, Elizabeth
    Vesole, David H.
    McBride, Laura
    Schmidt, Linda
    Gao, Zhijie
    Gilani, Madiha
    McNeill, Ann
    Bednarz, Urszula
    Richter, Joshua
    Mato, Anthony
    Graef, Thorsten
    Siegel, David S.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (10): : 558 - 562
  • [6] Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma
    Richter, Joshua R.
    Bilotti, Elizabeth
    McBride, Laura
    Schmidt, Linda
    Gao, Zhijie
    Tufail, Madiha
    Anand, Palka
    McNeill, Ann
    Bednarz, Urszula
    Graef, Thorsten
    Vesole, David H.
    Siegel, David S.
    [J]. BLOOD, 2011, 118 (21) : 1706 - 1706
  • [7] Erratum: Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Nikhil C Munshi
    Constantine Mitsiades
    Paul G Richardson
    Kenneth C Anderson
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 493 - 493
  • [8] Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
    Palumbo, Antonio
    Dimopoulos, Meletios
    San Miguel, Jesus
    Harousseau, Jean-Luc
    Attal, Michel
    Hussein, Mohamad
    Knop, Stefan
    Ludwig, Heinz
    von Lilienfeld-Toal, Marie
    Sonneveld, Pieter
    [J]. BLOOD REVIEWS, 2009, 23 (02) : 87 - 93
  • [9] Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Vesole, David H.
    Bilotti, Elizabeth
    Richter, Joshua R.
    McNeill, Ann
    McBride, Laura
    Raucci, Laura
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    Smith, Judith
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Mato, Anthony
    Siegel, David S.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 52 - 59
  • [10] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (vol 4, e182, 2014)
    Siegel, D. S.
    Richardson, P.
    Dimopoulos, M.
    Moreau, P.
    Mitsiades, C.
    Weber, D.
    Houp, J.
    Gause, C.
    Vuocolo, S.
    Eid, J.
    Graef, T.
    Anderson, K. C.
    [J]. BLOOD CANCER JOURNAL, 2014, 4 : e202 - e202
12345